TG Therapeutics (NASDAQ:TGTX) Price Target Increased to $20.00 by Analysts at The Goldman Sachs Group

TG Therapeutics (NASDAQ:TGTX) had its target price lifted by stock analysts at The Goldman Sachs Group from $18.00 to $20.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target suggests a potential downside of 4.49% from the company’s current price.

TGTX has been the topic of a number of other reports. LADENBURG THALM/SH SH increased their price objective on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. B. Riley raised their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. restated an “overweight” rating and issued a $25.00 price target on shares of TG Therapeutics in a research report on Thursday, April 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Stock Performance

TG Therapeutics stock traded up $0.36 during trading hours on Wednesday, hitting $20.94. The stock had a trading volume of 2,505,828 shares, compared to its average volume of 3,658,472. The company has a 50-day moving average of $18.54 and a two-hundred day moving average of $16.57. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63. The company has a market cap of $3.24 billion, a PE ratio of 91.57 and a beta of 2.23. TG Therapeutics has a fifty-two week low of $6.46 and a fifty-two week high of $23.12.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same period in the prior year, the firm posted ($0.34) EPS. TG Therapeutics’s quarterly revenue was up 357.0% compared to the same quarter last year. On average, equities research analysts anticipate that TG Therapeutics will post -0.01 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. New York State Common Retirement Fund raised its position in TG Therapeutics by 1.2% during the fourth quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock valued at $960,000 after purchasing an additional 663 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 1,322 shares during the last quarter. Valeo Financial Advisors LLC grew its stake in shares of TG Therapeutics by 2.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company’s stock worth $1,081,000 after purchasing an additional 1,500 shares during the last quarter. Swiss National Bank grew its stake in shares of TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 1,500 shares during the last quarter. Finally, nVerses Capital LLC grew its stake in shares of TG Therapeutics by 34.9% in the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.